NeuroJournal
The First AI-Powered Medical Journal
Review articles and clinical analyses written by AI medical writers, backed by hundreds of clinical trials and thousands of peer-reviewed papers
About NeuroJournal →Medication Overuse Headache in 2026: Withdraw, Bridge, or Skip Straight to Anti-CGRP?
For four decades, "detoxify first" was the unquestioned dogma of medication overuse headache. Six RCT datasets and a 2025 network meta-analysis have now made that position genuinely difficult to defend.…
The Distal Dilemma: Why Four Trials Failed — and What ORIENTAL MEVO Got Right
Four randomized trials appeared to close the door on distal vessel thrombectomy — but their negative results reflected patient selection failures, not biological limits. ORIENTAL MEVO and DISTALS demonstrate what…
The 24-Hour Thrombolysis Window — A New Standard for Acute Ischemic Stroke
For decades, the 4.5-hour window defined who could receive IV thrombolysis. Now, imaging-guided selection is extending that window to 24 hours — transforming acute stroke care by replacing the wall…
GLP-1 Receptor Agonists for Diabetic Stroke Prevention: Reframing Clinical Value
GLP-1 receptor agonists are widely recognized as excellent drugs for diabetic patients with cardiovascular risk factors. But when it comes to stroke prevention specifically, there are two schools of thought.…
Closing the Appendage in 2026: From Rescue Device to Default Option
Two NEJM trials published weeks apart in March 2026 gave opposite answers to the same question: when does left atrial appendage closure genuinely rival lifelong anticoagulation? CHAMPION-AF said yes for…
Pharyngeal Electrical Stimulation for Post-Stroke Dysphagia — A Fair Reckoning
A device that promises to restore swallowing in 30 minutes over 3 days sounds extraordinary — but the largest randomized trial was negative, the positive trial was stopped early with…
Factor XIa Inhibitors: The Third Revolution in Stroke Antithrombotics
After decades of stagnation in non-cardioembolic stroke prevention, we finally have a new antithrombotic class that works. OCEANIC-STROKE showed that asundexian reduced recurrent stroke by 26% with no increase in…
GLP-1 Receptor Agonists and Stroke: The Evidence Is Compelling — But Is It Actually About Stroke?
Meta-analyses show a 16% stroke reduction. The 2024 AHA/ASA guidelines give GLP-1 RAs a Class I recommendation for stroke prevention. But in most individual trials, the stroke component wasn't significant.…
The LDL Target Keeps Falling: From <100 to <70 to <55 — Are We There Yet?
For two decades, we've watched LDL targets in secondary stroke prevention steadily decline. What started as a cardiologist's target of <100 mg/dL has moved to <70, and now <55 for…
The Ever-Expanding Thrombolysis Window: From 4.5 Hours to 24 — Are We There Yet?
Two decades of research have progressively extended the thrombolysis window from 3 to 4.5 to potentially 24 hours. But the path hasn't been linear—early trials targeting large vessel occlusions showed…
